Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When would you use ofatumumab for anti-NMDAR autoimmune encephalitis?
In light of publication from Guo et al in Ann Neurol 2025 Jul
https://doi.org/10.1002/ana.27218
Related Questions
What are your preferred treatments for relapsing remitting multiple sclerosis with comorbid IBD?
How does lack of success of rituximab treatment affect your decision to trial anti-CD19 therapies like inebilizumab?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
When should patients be referred for advanced MRI testing to assess for CVS and PRL?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
What biomarkers best predict the response to B-cell depleting therapies in MS?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
What are best practices to avoid misdiagnosis of multiple sclerosis in patients over 50 years old?
How do you counsel patients interested in primary prevention of MS?
Which patients will have earlier diagnosis of multiple sclerosis via the new 2024 McDonald Criteria?